HC Wainwright Cuts Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO) – Equities researchers at HC Wainwright lowered their Q3 2026 EPS estimates for Sutro Biopharma in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($2.38) for the quarter, down from their previous estimate of ($2.32). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($9.06) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q4 2026 earnings at ($2.46) EPS, FY2027 earnings at ($4.69) EPS, FY2028 earnings at ($7.07) EPS, FY2029 earnings at ($4.94) EPS and FY2030 earnings at ($5.09) EPS.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($2.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The company had revenue of $9.84 million for the quarter, compared to analyst estimates of $11.96 million.

A number of other research analysts also recently issued reports on STRO. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Wednesday, August 5th. Stifel Nicolaus set a $48.00 price target on shares of Sutro Biopharma and gave the stock a “buy” rating in a research note on Friday, August 7th. Mizuho set a $50.00 price objective on Sutro Biopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Wall Street Zen downgraded Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, June 14th. Finally, Barclays started coverage on Sutro Biopharma in a report on Thursday, May 28th. They set an “overweight” rating and a $56.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sutro Biopharma presently has an average rating of “Buy” and an average price target of $47.30.

Sutro Biopharma Stock Performance

Shares of Sutro Biopharma stock opened at $21.31 on Friday. Sutro Biopharma has a 52 week low of $7.15 and a 52 week high of $43.85. The stock has a market capitalization of $353.11 million, a PE ratio of -1.93 and a beta of 1.55. The stock has a 50 day moving average price of $26.98 and a two-hundred day moving average price of $25.99.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Affinity Asset Advisors LLC boosted its holdings in shares of Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after buying an additional 321,137 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in Sutro Biopharma in the first quarter valued at $17,818,000. Orbimed Advisors LLC purchased a new position in Sutro Biopharma in the 1st quarter valued at approximately $19,956,000. Spruce Street Capital LP purchased a new stake in shares of Sutro Biopharma in the fourth quarter valued at about $875,000. Finally, ADAR1 Capital Management LLC increased its position in Sutro Biopharma by 681.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock worth $13,064,000 after purchasing an additional 457,364 shares in the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $60 price target, while HC Wainwright reiterated its “Buy” rating and $50 target. These targets imply substantial potential upside if Sutro’s pipeline advances successfully. Benzinga analyst coverage
• Positive Sentiment: HC Wainwright improved its longer-term loss forecasts for fiscal 2027 through 2030. Estimated losses were narrowed to $4.69 per share for 2027, $7.07 for 2028, $4.94 for 2029 and $5.09 for 2030, suggesting expectations for better future operating performance than previously modeled.
• Neutral Sentiment: Citizens JMP lowered its price target from $41 to $34 but retained a “Market Outperform” rating. The reduced target reflects more cautious valuation assumptions, although the firm still sees meaningful upside from current levels. Citizens JMP price target update
• Negative Sentiment: HC Wainwright lowered its projected third- and fourth-quarter 2026 losses to $2.38 and $2.46 per share, respectively, compared with prior estimates of $2.32 for each quarter. The revisions indicate higher expected near-term expenses and extend the company’s path to profitability.
• Negative Sentiment: Sutro’s recent quarterly results missed expectations, with a loss of $2.33 per share versus the $2.19 consensus estimate and revenue of $9.84 million versus estimates of $11.96 million. The company’s clinical update on the STRO-004 Phase 1 study also raised investor concerns, contributing to selling pressure. Why Sutro Biopharma stock is falling

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.